Ampersand Capital Partners in Wellesley, Massachusetts announced the $670 million closing of its private equity strategy dedicated to growth-oriented investments within the healthcare sector.
The Ampersand Continuation Fund was oversubscribed and formed to acquire the equity interests of three portfolio companies previously held by multiple mature Ampersand funds. A core asset in the fund is in Confluent Medical Technologies.
Confluent Medical is known for its precision contract manufacturing of specialized medical devices. Its portfolio of services includes complex catheters, stent delivery systems, Nitinol components, biomedical textiles, balloon expandable stents, balloon catheters and guidewires. . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.
